COVID-19

Although COVID-19 generally causes milder illness in children than in adults, severe disease, hospitalization and long-term complications can occur, particularly among infants and children with underlying health conditions. Despite this burden, children have historically been underrepresented in COVID-19 therapeutic research, resulting in limited evidence and a lack of age-appropriate treatment options. To address these gaps, WHO convened a Paediatric Drug Optimization (PADO) exercise for COVID-19 in September 2022, bringing together experts and key stakeholders to identify priority medicines and research needs. The exercise prioritized nirmatrelvir-ritonavir, tocilizumab and baricitinib for further paediatric investigation and development, highlighting critical gaps in dosing, safety, efficacy and age-appropriate formulations. The outcomes aimed to guide coordinated research and development efforts and accelerate equitable access to optimized COVID-19 treatments for children.

Fig. 1. PADO-COVID-19 list of priority products for research and development

Nirmatrelvir-ritonavir

  • Robust efficacy data in preventing COVID-19 progression
  • Oral formulation
  • Short duration of treatment
  • Ideal for high-risk children

Tocilizumab

  • Strong efficacy data in moderate and severe COVID-19
  • Reassuring and robust safety data for children
  • Single dose treatment

Baricitinib

  • Strong efficacy data in moderate and severe COVID-19
  • Safety has been studied among children (non-COVID)
  • Short half-life and oral formulation

Contact

Janet Diaz
Email: diazj@who.int